Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie - 2Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- 3The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- 4Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- 5US FDA grants market authorization to six on! PLUS nicotine pouch products
- A milestone for Artemis II: Astronauts enter the 'lunar sphere of influence'
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Instructions to Plan for Your Teeth Substitution Methodology
- Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks
- Israel strikes south Lebanon after first direct talks in decades
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
